COMPANY PROFILE · /generate-biomedicines
G
Generate Biomedicines
Clinical-stage biotech pioneering Generative Biology—using diffusion and graph-based AI models integrated with scalable biohardware (cell-free expression, multiplexed assays, cryo-EM core) to design protein therapeutics de novo. Platform combines design–build–test–learn loop for rapid therapeutic validation.
Fresh · 5d ago
Latest valuation
—
Annual Recurring Revenue
—
Headcount
312 (138 PhD/MD holders)
Funding total
$400M+
OVERVIEW
IPO filed Feb 2026; lead candidate GB-0895 (anti-TSLP antibody) in Phase 3 for severe asthma; Chroma de novo protein design published in Nature 2023; Platform partnerships with Amgen (6 programs) and Novartis.
Status
active
Tier
master-list
Profitability
loss-making
Pricing
enterprise
FUNDING HISTORY · 0
No funding rounds on file.
PRODUCTS · 0
No products catalogued yet. Press Refresh above to ask the research agent.
TEAM · 0 key people
No people linked.
SOURCES · 0 cited
No citations stored yet. Run the research agent to attach per-claim sources.